Inventor · disambiguated record
Shu Wen Samantha Ho
Also filed as: HO SHU WEN SAMANTHA
4 granted patents·6 pending applications·22 citations·filing 2018–2024
73Inventor score
Files withCHUGAI PHARMACEUTICAL CO LTD10
Top patents by PatentIndex Score
10 records- 0195US11274151B2CD3-targeting and DLL3-targeting multispecific antigen-binding molecules and uses thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Granted Mar 15, 2022·11 cites·28 claims
- 0294US11718672B2CD137- and DLL3-targeting multispecific antigen-binding moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Granted Aug 8, 2023·6 cites·28 claims
- 0388US11952422B2Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137CHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Apr 9, 2024·4 cites·15 claims
- 0475US12509524B2Antigen-binding molecule comprising altered antibody variable regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Granted Dec 30, 2025·1 cites·21 claims
- 0575US2024010725A1Dll3-targeting multispecific antigen-binding molecules and uses thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0668US2024239890A1Cytotoxicity-inducing therapeutic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0767US2024270846A1Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137CHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 0858US2024400721A1Uses of dll3-targeting multispecific antigen-binding moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0948US2020123256A1Cytotoxicity-inducing therapeutic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Application pending·0 cites
- 1043US2021388087A1Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneouslyCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Shu Wen Samantha Ho files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →